HST
34
-3
AA
56
3
RL
66
-3
D
23
-2
JNJ
50
-3
XYL
39
6
HBI
59
-5
TRIP
52
3
ABT
60
-3
DOW
32
-2
ES
21
-3
CVS
53
-3
MSI
50
-5
UNH
50
-2
STX
49
-3
ABBV
53
-7
MUR
44
2
PEG
51
-7
CAG
48
-5
LUV
59
-3
HST
34
-3
AA
56
3
RL
66
-3
D
23
-2
JNJ
50
-3
XYL
39
6
HBI
59
-5
TRIP
52
3
ABT
60
-3
DOW
32
-2
ES
21
-3
CVS
53
-3
MSI
50
-5
UNH
50
-2
STX
49
-3
ABBV
53
-7
MUR
44
2
PEG
51
-7
CAG
48
-5
LUV
59
-3
Financhill
Back

Sangamo Therapeutics 10K Form

Sell
25

SGMO
Sangamo Therapeutics

Last Price:
$0.85
Seasonality Move:
-4.44%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SGMO News And Ratings

See the #1 stock for the next 7 days that we like better than SGMO

SGMO Financial Statistics

Sales & Book Value

Annual Sales: $57.8M
Cash Flow: $-3.5M
Price / Cash Flow: 0
Annual Sales: $0.11
Price / Book: 8.28

Profitability

EPS (TTM): -0.52000
Net Income (TTM): $-97.9M
Gross Margin: $0
Return on Equity: -217.48%
Return on Assets: -81.59%

Sangamo Therapeutics Earnings Forecast

Key Sangamo Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 18 years for SGMO is 0.00%.
  • The Selling, General & Administrative Expenses for SGMO have been equal to 77.38% of Gross Profit Margin.
  • The Research & Development expenses have been 192.94% of Revenue.
  • The Net Earning history of SGMO is -169.45% of Total Revenues.
  • Per Share Earnings over the last 29 years have been positive in 8 years.

Sangamo Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SGMO
CUSIP: 800677
Website: sangamo.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.13
Quick Ratio: 1.02

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SGMO Technical Analysis vs Fundamental Analysis

Sell
25
Sangamo Therapeutics (SGMO) is a Sell

Is Sangamo Therapeutics a Buy or a Sell?